Commenting on SMC’s decision, XLH UK founder Oliver Gardiner explained that “This is fantastic news for adults with XLH in Scotland and is a leap forward, setting a precedent as the first of the UK nations to recommend burosumab for the eligible adult population. This life-changing treatment is the first to tackle the underlying problem, with the potential to lessen the significant physical and emotional challenges that adults with XLH are faced with on a daily basis.”

Please read our press release below.

You can view it here: